KOL

SOMO -- Revolutionizing the Global Influencer Industry with Intelligent Solutions

Retrieved on: 
Thursday, December 21, 2023
Marketing, WARC, Partnership, Multimedia, Quality control, AI, SOMO, Northern Beaches, Internet, KOL, Online shopping

HONG KONG, Dec. 21, 2023 /PRNewswire/ -- BlueFocus, a trailblazer in the marketing industry, is actively exploring how the Metaverse and AI will shape the future landscape of marketing in the coming decade. Today, on a global scale, WARC recognizes BlueFocus among the top 10 advertising agencies, notably as the sole representative from China.

Key Points: 
  • SOMO boasts a robust influencer search engine, offering comprehensive solutions for global brand clients.
  • SOMO emphasizes quality control, transparency, and innovation, exemplified by one-click connections, real-time monitoring, and SOMO Community's global reach for mutual brand-influencer success.
  • Meanwhile, under the BlueFocus umbrella, SOMO, the premier marketing service platform for global influencer transactions, proudly introduces SOMO Community.
  • The platform provides comprehensive influencer marketing solutions, solidifying its position as the go-to choice for global brand clients.

Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023

Retrieved on: 
Wednesday, November 15, 2023
Therapy, PSTV, Glioblastoma, Patient, Neuro, Conference, Plus Therapeutics, Rhenium, Neurosurgery, Neuro-oncology, Neurology, Society, SNO, KOL, Decompression (diving), Pharmaceutical industry, Medicine

To register, click here.

Key Points: 
  • To register, click here.
  • The event will feature presentations from neuro-oncology expert and principal investigator Andrew Brenner, M.D., Ph.D. (Professor-Research, Departments of Medicine, Neurology, and Neurosurgery & S & B Kolitz/CTRC-Zachry Endowed Chair Neuro-Oncology Research, Mays Cancer Center at UT Health San Antonio) and neurosurgeons Toral Patel, M.D.
  • Brain Institute) and John Floyd, M.D.
  • A live question and answer session will follow the formal presentations.

Bio-Path Holdings Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 15, 2023
Acute myeloid leukemia, Clinical trial, Patient, Research, MD Anderson Cancer Center, D.O, Division, AML, Holding, Interim analysis, KOL, Pharmaceutical industry, Cryptocurrency, Decitabine

HOUSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments.

Key Points: 
  • HOUSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments.
  • Announced Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia.
  • As of September 30, 2023, the Company had cash of $2.4 million, compared to $10.4 million as of December 31, 2022.
  • ET to review these third quarter 2023 financial results and to provide a general update on the Company.

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023
Well, Neck, Annual general meeting, DNA, Cervical cancer, Castration, ICI, PSA, ADC, Patient, Research, Lymph, E pluribus unum, Neoplasm, Cytokine, Cancer, Pembrolizumab, Oncology, Doctor of Philosophy, OS, Burtness, Webcast, Safety, Fourth grade, Food, Head, International, Radiation, PDS, Infection, Society, SOC, PDSB, KOL, Opinion, National Cancer Institute, IL12, Recurrence, CRT, CD8, Ferret, Nivolumab, Squamous-cell carcinoma, Biomarker, Standard works, HDAC, Clinical trial, NCI, FDA, Biotechnology, Vaccine, Prostate cancer, Immunotherapy, Survival, TH1, Prostate-specific antigen, Cetuximab, HPV, Docetaxel, Pharmaceutical industry, Medical imaging, Birth control, H1N1

The Company will provide a business update on its conference call and webcast at 8:00 AM EST today.

Key Points: 
  • The Company will provide a business update on its conference call and webcast at 8:00 AM EST today.
  • PDS Biotech anticipates initiation of VERSATILE-003 in Q1 2024.
  • PDS Biotech’s cash balance as of September 30, 2023 was approximately $54.3 million.
  • PDS Biotech believes that, with initiating the VERSATILE-003 Phase 3 clinical trial in the first quarter of 2024, its available cash resources will sustain operational and research and development endeavors into the third quarter of 2024.

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

Retrieved on: 
Monday, November 13, 2023
Durvalumab, Neck, Research, NYSE, Shield, GMP, Safety, Telephone, Head, Conference call, Clinical trial, ESMO, HCT, Patient, FDA, Cancer, VCN, Therapy, Conference, University, SITC, Survival, Congress, CPS, KOL, ICO, Travel, University of Pennsylvania, Pharmaceutical industry, Cryptocurrency, PDAC

ET -

Key Points: 
  • ET -
    ROCKVILLE, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
  • Third Quarter Ended September 30, 2023 Financial Results
    General and administrative expenses decreased to $212,000 for the three months ended September 30, 2023, from $2.4 million for the three months ended September 30, 2022.
  • Theriva Biologics will host a conference call on Monday, November 13, 2023, at 8:30 a.m.
  • ET to discuss its financial results for the quarter ended September 30, 2023 and provide a corporate update.

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
Johns Hopkins University, Deltex Medical Group, Annual general meeting, Pakistan Society of Neuro-Oncology, Progression-free survival, University, HSCT, ASH, Cohort, Glioblastoma, TTP, IND, GBM, Leukemia, Patient, Research and development, Abstract, Cleveland Clinic, PFS, Research, Immunotherapy, CRS, IPSC, ORR, CD33, Ovarian cancer, Cancer, Development, CML, Survival, Bone marrow, SITC, Arms, AML, Gamma delta T cell, Society, SNO, CD123, Poster, KOL, University of Chicago, DRI, Pharmaceutical industry, Medical imaging

Updated Phase 1 clinical data from INB-200 to be presented at Society for Neuro-Oncology (SNO) on November 17, 2023.

Key Points: 
  • Updated Phase 1 clinical data from INB-200 to be presented at Society for Neuro-Oncology (SNO) on November 17, 2023.
  • NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced financial results, operational highlights and recent corporate developments for the third quarter ended September 30, 2023.
  • The presentation at ASH will highlight clinical data updating the efficacy results of INB-100 including complete responses (CRs) and durability.
  • Cash: As of September 30, 2023, the Company had cash of $12.9 million, compared to $17.0 million as of June 30, 2023.

Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, November 9, 2023
HERG, Synthetic lethality, DDR, Acquisition, Safety, MD Anderson Cancer Center, WEE1, Therapy, University, PLK3, Gynecologic oncology, IND, ATR, PLK, Patient, PLK1, Division, FDA, Conference, Cardiotoxicity, Cell death, Ovarian cancer, APRE, Anemia, Poster, KOL, PLK2, AACR, Pharmaceutical industry, Aprea-Cuccaro clan

DOYLESTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and nine months ended September 30, 2023, and provided a business update.

Key Points: 
  • DOYLESTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and nine months ended September 30, 2023, and provided a business update.
  • “We are very pleased by the progress of our diversified programs this past quarter.
  • “We are continuing with patients in the dose escalation portion of the study, and the dose expansion cohort is on track to be initiated in 2Q 2024.
  • The first poster included initial data from the Company’s first-in-human Phase 1/2a dose escalation trial of ATRN-119 in solid tumors.

MaaT Pharma to Host Virtual KOL Event on MaaT013 and MaaT033 Following ASH 2023 Presentations

Retrieved on: 
Tuesday, December 12, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Safety, ASH, Hospital, Patient, CET, Hematopoietic stem cell transplantation, Hematology, Register, Cancer, Survival, MET, EST, Sorbonne University, KOL, Special access program, Pharmaceutical industry

---

Key Points: 
  • MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, announced that it will host a virtual KOL (Key Opinion Leader) event on data presented during the 2023 ASH annual meeting including efficacy and safety results for its lead drug candidate, MaaT013, currently in development for acute Graft-versus-Host Disease (aGvHD) and details on MaaT033, developed as an adjuvant therapy to improve patients’ survival following allogeneic hematopoietic stem cell transplantation (allo-HSCT), on Monday, December 18, 2023, at 6:00 pm CET (12:00 pm EST).
  • The event will feature presentations from the Company’s CEO and co-founder, Hervé Affagard as well as the following KOLs:
    Mohamad Mohty, M.D., Ph.D., Professor of Hematology at Sorbonne University, and head of the Clinical Hematology and Cellular Therapy Department at Saint-Antoine Hospital, Paris, France will comment on the positive data on MaaT013 presented for the Early Access Program; and
    Florent Malard, M.D., Ph.D., Professor of Hematology at the Saint-Antoine Hospital and Sorbonne University, Principal investigator of Phase 2b trial evaluating MaaT033 in patients receiving allo-HSCT, will provide detailed information on the ongoing trial.
  • Registration & link to access the event: https://app.livestorm.co/newcap-1/maat-pharma-presentation?type=detailed
    A replay will be made available on the Company’s website for at least 90 days.

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Retrieved on: 
Sunday, December 10, 2023
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Principal, Caregiver, Patient, KOL, Bone marrow, Hematopoietic stem cell transplantation, ASH, Division

“The rapid and durable responses observed in the Phase 2 TELLOMAK trial which enrolled heavily pretreated patients, confirms that treatment with lacutamab achieves clinically meaningful outcomes for patients with Sézary Syndrome after at least two prior systemic therapies,” commented Dr. Sonia Quaratino, Chief Medical Officer of Innate Pharma.

Key Points: 
  • “The rapid and durable responses observed in the Phase 2 TELLOMAK trial which enrolled heavily pretreated patients, confirms that treatment with lacutamab achieves clinically meaningful outcomes for patients with Sézary Syndrome after at least two prior systemic therapies,” commented Dr. Sonia Quaratino, Chief Medical Officer of Innate Pharma.
  • It is promising to see lacutamab achieving remarkable efficacy along with favorable safety in this heavily pre-treated population.
  • We thank the investigators, clinical research coordinators, patients and caregivers involved in the TELLOMAK program.”
    Innate Pharma will host a virtual KOL event, featuring Prof. Pierluigi Porcu, on lacutamab, highlighting results from ASH oral presentation on Tuesday, December 12, 2023 at 7:00AM PST (4:00PM CET).
  • The live webcast will be available at the following link:

Innate Pharma to Host Virtual KOL Event on Lacutamab

Retrieved on: 
Monday, November 27, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Euronext Paris, Annual general meeting, CTCL, Bone marrow, Progression-free survival, ASH, Cutaneous T-cell lymphoma, Cutaneous lymphoma, Patient, Hematopoietic stem cell transplantation, Division, IPH, Blood, Lymphoma, ORR, Doctor of Philosophy, Society, Skin, IPHA, KOL, PTCL, ITT, Education, Pharmaceutical industry

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host a virtual KOL (Key Opinion Leader) event on lacutamab, a first-in-class anti-KIR3DL2 antibody currently in development for cutaneous T-cell lymphoma (CTCL) and peripheral T cell lymphoma (PTCL), on Tuesday, December 12, 2023, at 7:00AM PST (4:00PM CET).

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host a virtual KOL (Key Opinion Leader) event on lacutamab, a first-in-class anti-KIR3DL2 antibody currently in development for cutaneous T-cell lymphoma (CTCL) and peripheral T cell lymphoma (PTCL), on Tuesday, December 12, 2023, at 7:00AM PST (4:00PM CET).
  • Prof. Porcu is a Lymphoma-focused hematologic oncologist with a long track record of advocacy and education for patients with cutaneous lymphoma.
  • Sonia Quaratino, M.D., PhD, Chief Medical Officer of Innate Pharma, will host the call.
  • In the Intention to treat population (ITT), the global confirmed objective response rate (ORR) was 37.5% (21/56).